Dr
Sophie-Beth
Aylett

Senior Patent Attorney

London Office

Life sciences

Telephone. +44 (0)207 776 5100
Email. [email protected]

Experience

Sophie-Beth is a Chartered (UK) Patent Attorney and European Patent Attorney in the biotechnology and life sciences fields with particular specialist knowledge in immunotherapy, antibodies, cancer therapeutics, vaccines and diagnostics. She has extensive experience advising a range of clients including first-time inventors, start-ups and SME's to large established corporations and overseas associates.

Sophie-Beth acts before the UKIPO, EPO and WIPO. Her work includes drafting, filing and prosecuting patent applications, post-grant opposition and appeal proceedings before the EPO and matters relating to IP due diligence. Sophie-Beth focuses on providing commercially relevant, pragmatic advice to clients in line with their business objectives and is proactive in coordinating the strategic planning and management of clients' patent portfolios.

Sophie-Beth is a member of the HGF Venture team with Kerry Rees and provides IP due diligence service to life science investors. Consequently, Sophie-Beth also works with early stage companies to help them align their IP strategies with their business plan to maximise the return on investment.

Sophie-Beth graduated with a first class degree in Pharmacology from the University of Bath. As part of her degree, she spent a year working at a leading biopharmaceutical company, UCB. Sophie-Beth then went on to gain a PhD in Metabolic Biochemistry from University College London. Her research focused on the genetic and biochemical mechanisms responsible for the central folate deficiency associated with mitochondrial disorders.

Qualifications

Patent Attorney

Chartered (UK)
Europe


MSCI

MPharmacol (Hons) in Pharmacology

PHD

PhD in Metabolic Biochemistry

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate in Intellectual Property Law

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Basic Litigation Skills

Related News

From Theoretical Proposals to Commercial Reality: The Rise of Innovation and Patent Filings in Quantum Computing

The possibility of quantum computing was first seriously proposed in the early 1980s and is widely regarded as having enormous potential to deliver a step change in the complexity of …

Read article
Event - 3rd February 2023

The European Patent Office are running an inspiring collaborative art competition for children

To celebrate the 50th anniversary of the signing of the European Patent Convention, The European Patent Office (EPO) is running a collaborative art competition for primary schools on the topic …

Event details
Event - 8th-9th February 2023

5th Annual Microbiome & Probiotic Conference 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …

Event details
Event - 17th January 2023

CIPA Webinar: Enhancing Diversity in the Patent Profession How Can I Help

CIPA hosted a webinar to discuss ‘Enhancing diversity in the patent profession.’ Date Tuesday 17 January, 2023 Time 12.30pm – 1.30pm (GMT) Equity, diversity and inclusion has been in the …

Event details

LiDAR: A Significant Support Technology at CES

When visiting CES’ one thing that struck me was the number of companies demonstrating LiDAR technology. LiDAR has been around since the 1960s and was originally developed for aerospace use, …

Read article

Healthcare and Climate Change

Can we find a balance between intellectual property rights and public health needs when tackling the climate crisis? “The world faces a critical juncture. A health-centred, aligned response to the …

Read article

Navigating the CRISPR IP confusion

It is just over 10 years since the Science publication of Jinek et al. showed for the first time that DNA cleavage could be achieved in vitro with a Cas9 …

Read article

CRISPR Edited T cells win the TvT Battle

T-cells which have been modified using CRISPR base editing technology have been successfully used to treat T-cell acute lymphoblastic leukaemia for the first time {1}. A 13 year old patient …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.